PubRank

Roman A Blaheta

Author PubWeight™ 36.92‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 CXCR4 chemokine receptor mediates prostate tumor cell adhesion through alpha5 and beta3 integrins. Neoplasia 2006 1.52
2 Valproic acid inhibits angiogenesis in vitro and in vivo. Mol Pharmacol 2004 1.41
3 Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 2005 1.20
4 Resistance after chronic application of the HDAC-inhibitor valproic acid is associated with elevated Akt activation in renal cell carcinoma in vivo. PLoS One 2013 1.02
5 Impact of combined HDAC and mTOR inhibition on adhesion, migration and invasion of prostate cancer cells. Clin Exp Metastasis 2011 1.00
6 Inhibitory effects of the HDAC inhibitor valproic acid on prostate cancer growth are enhanced by simultaneous application of the mTOR inhibitor RAD001. Life Sci 2010 0.97
7 CXCR4 chemokine receptor engagement modifies integrin dependent adhesion of renal carcinoma cells. Exp Cell Res 2007 0.96
8 Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 2005 0.95
9 The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line. Cancer Lett 2011 0.95
10 Acetylation of histone H3 prevents resistance development caused by chronic mTOR inhibition in renal cell carcinoma cells. Cancer Lett 2012 0.95
11 Combining the receptor tyrosine kinase inhibitor AEE788 and the mammalian target of rapamycin (mTOR) inhibitor RAD001 strongly inhibits adhesion and growth of renal cell carcinoma cells. BMC Cancer 2009 0.94
12 The histone deacetylase inhibitor valproic acid alters growth properties of renal cell carcinoma in vitro and in vivo. J Cell Mol Med 2008 0.94
13 Molecular targeting of prostate cancer cells by a triple drug combination down-regulates integrin driven adhesion processes, delays cell cycle progression and interferes with the cdk-cyclin axis. BMC Cancer 2011 0.89
14 Valproic acid blocks adhesion of renal cell carcinoma cells to endothelium and extracellular matrix. J Cell Mol Med 2009 0.88
15 Interleukin-4, interleukin-10, and interleukin-1-receptor antagonist but not transforming growth factor-beta induce ramification and reduce adhesion molecule expression of rat microglial cells. J Neurosci Res 2002 0.88
16 HDAC inhibition delays cell cycle progression of human bladder cancer cells in vitro. Anticancer Drugs 2011 0.88
17 CXC chemokine mRNA expression as a potential diagnostic tool in prostate cancer. Mol Med Rep 2011 0.87
18 Elevation of circulating HLA DR(+) CD8(+) T-cells and correlation with chromium and cobalt concentrations 6 years after metal-on-metal hip arthroplasty. Acta Orthop 2010 0.85
19 Effects of combined valproic acid and the epidermal growth factor/vascular endothelial growth factor receptor tyrosine kinase inhibitor AEE788 on renal cell carcinoma cell lines in vitro. BJU Int 2009 0.85
20 Altered expression of beta1 integrins in renal carcinoma cell lines exposed to the differentiation inducer valproic acid. Int J Mol Med 2006 0.83
21 Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells. J Cell Mol Med 2014 0.83
22 Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells. Int Immunopharmacol 2005 0.82
23 Expression of angiogenesis inhibitors in human bladder cancer may explain rapid metastatic progression after radical cystectomy. Int J Mol Med 2009 0.82
24 Low dosed interferon alpha augments the anti-tumor potential of histone deacetylase inhibition on prostate cancer cell growth and invasion. Prostate 2012 0.81
25 Critical analysis of simultaneous blockage of histone deacetylase and multiple receptor tyrosine kinase in the treatment of prostate cancer. Prostate 2010 0.81
26 Publication of original research in urologic journals--a neglected orphan? PLoS One 2012 0.81
27 Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application. Liver Int 2007 0.81
28 Combined targeting of the VEGFr/EGFr and the mammalian target of rapamycin (mTOR) signaling pathway delays cell cycle progression and alters adhesion behavior of prostate carcinoma cells. Cancer Lett 2010 0.81
29 Modulation of adhesion and growth of colon and pancreatic cancer cells by the histone deacetylase inhibitor valproic acid. Int J Mol Med 2008 0.81
30 Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib. J Cell Mol Med 2014 0.81
31 An endogenous inhibitor of angiogenesis derived from a transitional cell carcinoma: clipped beta2-glycoprotein-I. Ann Surg Oncol 2006 0.80
32 Chemokines involved in tumor promotion and dissemination in patients with renal cell cancer. Cancer Biomark 2011 0.80
33 Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes. J Cell Mol Med 2007 0.80
34 HDAC inhibition suppresses bladder cancer cell adhesion to collagen under flow conditions. Exp Biol Med (Maywood) 2013 0.80
35 Preservation of the synthetic and metabolic capacity of isolated human hepatocytes by coculture with human biliary epithelial cells. Liver Transpl 2005 0.79
36 Modulation of the CXC-chemokine expression profile on tumor cells by the immunosuppressive drug mycophenolate mofetil. Int J Mol Med 2005 0.78
37 Development of urological cancers in renal transplant recipients: 30-year experience at the Frankfurt Transplant Center. Cancer Sci 2010 0.77
38 The prostate cancer blocking potential of the histone deacetylase inhibitor LBH589 is not enhanced by the multi receptor tyrosine kinase inhibitor TKI258. Invest New Drugs 2012 0.77
39 CCL2 promotes integrin-mediated adhesion of prostate cancer cells in vitro. World J Urol 2014 0.76
40 Maspin modulates adhesion of bladder carcinoma cells to vascular endothelium. World J Urol 2010 0.76
41 Valproate inhibits colon cancer growth through cell cycle modification in vivo and in vitro. Exp Ther Med 2011 0.76
42 Plasmin-clipped beta(2)-glycoprotein-I inhibits endothelial cell growth by down-regulating cyclin A, B and D1 and up-regulating p21 and p27. Cancer Lett 2010 0.76
43 Endothelial adhesion of synchronized gastric tumor cells changes during cell cycle transit and correlates with the expression level of CD44 splice variants. World J Gastroenterol 2005 0.75
44 Controlled and reversible induction of differentiation and activation of adult human hepatocytes by a biphasic culture technique. World J Gastroenterol 2005 0.75
45 c-Met responsiveness of isolated hepatocytes evaluated in an in vitro de-differentiation model. Int J Mol Med 2006 0.75
46 Phosphorylation of hepatocyte growth factor receptor and epidermal growth factor receptor of human hepatocytes can be maintained in a (3D) collagen sandwich culture system. Toxicol In Vitro 2004 0.75
47 Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion. Oncotarget 2017 0.75
48 Binding of gastrointestinal tumor cells to endothelial E- and P-selectin adhesion receptors leads to transient down-regulation of sLeX ligands in vitro. Int J Colorectal Dis 2003 0.75
49 Autocrine stimulation of human hepatocytes triggers late DNA synthesis and stabilizes long-term differentiation in vitro. Int J Mol Med 2008 0.75
50 Globalization in Urology: A Bibliographical Analysis of Cross-Continent Publication between 2002 and 2012. Urol Int 2015 0.75
51 Effect of procurement-related organ lesions on renal transplant outcome. Clin Transplant 2008 0.75